Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. 2004

S Matthijs Boekholdt, and Ron J G Peters, and Nicholas E Day, and Robert Luben, and Sheila A Bingham, and Nicholas J Wareham, and C Erik Hack, and Pieter H Reitsma, and Kay-Tee Khaw
Department of Cardiology, Academic Medical Center, Amsterdam, The netherlands.

OBJECTIVE To determine whether plasma levels of macrophage migration inhibitory factor, a proinflammatory cytokine involved in atherogenesis, are predictive of myocardial infarction or death from coronary artery disease. METHODS We performed a prospective case-control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort. We selected men and women who did not report a history of myocardial infarction or stroke at baseline. Baseline concentrations of macrophage migration inhibitory factor were measured among 777 patients who had a myocardial infarction or died of coronary artery disease during follow-up, and 1554 matched controls who remained free of coronary artery disease. RESULTS Baseline macrophage migration inhibitory factor concentrations were higher in cases than controls (median, 107.4 microg/L vs. 90.7 microg/L, P = 0.001). The risk of myocardial infarction or death from coronary artery disease increased with increasing quartiles of macrophage migration inhibitory factor (P for linearity <0.0001). Patients in the highest quartile had the greatest likelihood of myocardial infarction or death due to coronary artery disease (unadjusted odds ratio [OR] = 1.6; 95% confidence interval [CI]: 1.2 to 2.0). After adjustment for traditional risk factors and C-reactive protein level, the odds ratio decreased slightly (OR = 1.3; 95% CI: 1.0 to 1.7). Upon additional adjustment for white cell count, this association was no longer statistically significant. CONCLUSIONS Prospective data suggest that the relation between macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without a history of myocardial infarction or stroke is not very strong. However, the data support a regulatory role for macrophage migration inhibitory factor in the process of atherosclerosis.

UI MeSH Term Description Entries
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008263 Macrophage Migration-Inhibitory Factors Proteins released by sensitized LYMPHOCYTES and possibly other cells that inhibit the migration of MACROPHAGES away from the release site. The structure and chemical properties may vary with the species and type of releasing cell. Macrophage Migration Inhibitory Factor,Migration Inhibition Factors, Macrophage,Macrophage Migration Inhibition Factors,Migration Inhibition Factor, Macrophage,Macrophage Migration Inhibitory Factors,Migration-Inhibitory Factors, Macrophage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D005260 Female Females

Related Publications

S Matthijs Boekholdt, and Ron J G Peters, and Nicholas E Day, and Robert Luben, and Sheila A Bingham, and Nicholas J Wareham, and C Erik Hack, and Pieter H Reitsma, and Kay-Tee Khaw
September 2006, Journal of lipid research,
S Matthijs Boekholdt, and Ron J G Peters, and Nicholas E Day, and Robert Luben, and Sheila A Bingham, and Nicholas J Wareham, and C Erik Hack, and Pieter H Reitsma, and Kay-Tee Khaw
June 2017, Arteriosclerosis, thrombosis, and vascular biology,
S Matthijs Boekholdt, and Ron J G Peters, and Nicholas E Day, and Robert Luben, and Sheila A Bingham, and Nicholas J Wareham, and C Erik Hack, and Pieter H Reitsma, and Kay-Tee Khaw
December 2012, Arteriosclerosis, thrombosis, and vascular biology,
S Matthijs Boekholdt, and Ron J G Peters, and Nicholas E Day, and Robert Luben, and Sheila A Bingham, and Nicholas J Wareham, and C Erik Hack, and Pieter H Reitsma, and Kay-Tee Khaw
March 2006, Arteriosclerosis, thrombosis, and vascular biology,
S Matthijs Boekholdt, and Ron J G Peters, and Nicholas E Day, and Robert Luben, and Sheila A Bingham, and Nicholas J Wareham, and C Erik Hack, and Pieter H Reitsma, and Kay-Tee Khaw
January 2007, Journal of lipid research,
S Matthijs Boekholdt, and Ron J G Peters, and Nicholas E Day, and Robert Luben, and Sheila A Bingham, and Nicholas J Wareham, and C Erik Hack, and Pieter H Reitsma, and Kay-Tee Khaw
September 2010, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne,
S Matthijs Boekholdt, and Ron J G Peters, and Nicholas E Day, and Robert Luben, and Sheila A Bingham, and Nicholas J Wareham, and C Erik Hack, and Pieter H Reitsma, and Kay-Tee Khaw
April 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology,
S Matthijs Boekholdt, and Ron J G Peters, and Nicholas E Day, and Robert Luben, and Sheila A Bingham, and Nicholas J Wareham, and C Erik Hack, and Pieter H Reitsma, and Kay-Tee Khaw
November 2006, Journal of thrombosis and haemostasis : JTH,
S Matthijs Boekholdt, and Ron J G Peters, and Nicholas E Day, and Robert Luben, and Sheila A Bingham, and Nicholas J Wareham, and C Erik Hack, and Pieter H Reitsma, and Kay-Tee Khaw
December 2013, Arteriosclerosis, thrombosis, and vascular biology,
S Matthijs Boekholdt, and Ron J G Peters, and Nicholas E Day, and Robert Luben, and Sheila A Bingham, and Nicholas J Wareham, and C Erik Hack, and Pieter H Reitsma, and Kay-Tee Khaw
December 2010, Heart (British Cardiac Society),
Copied contents to your clipboard!